ILE Isolagen

Isolagen, Inc. to Present at Adams Harkness 25th Annual Summer Seminar EXTON, Pa., July 25 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) today announced that a live webcast of its presentation at the Adams Harkness 25th Annual Summer Seminar at the Marriott Long Wharf in Boston, MA is scheduled for Thursday, August 4, 2005 at 9:00 AM EDT. Members of the financial community, the media and other interested parties can access a live webcast of the presentation via a link on the Isolagen corporate website, http://www.isolagen.com/ . An archive of the webcast will be available on the Company's web site following the presentation. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and actual results may differ materially from the forward-looking statements. Isolagen, Inc. does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein. DATASOURCE: Isolagen, Inc. CONTACT: Mark A. Kahil, V.P., Investor Relations of Isolagen, Inc., +1-484-713-6050 Web site: http://www.isolagen.com/

Copyright